Insider plans $5.2M Ionis (NASDAQ: IONS) stock sale under Rule 144

Rhea-AI Filing Summary

Ionis Pharmaceuticals insider plans additional stock sale under Rule 144. A person associated with Ionis plans to sell 62,970 shares of common stock through broker Morgan Stanley Smith Barney on or about 01/30/2026 on NASDAQ, with an aggregate market value of 5,223,748.59.

The shares come from performance stock units granted under the company’s 2011 Equity Incentive Plan and delivered as compensation on 01/29/2026. During the prior three months, the same broker sold 44,034 shares of Ionis common stock for gross proceeds of 3,294,623.88 for the same account.

Insights

Equity capital markets analyst

Form 144 shows a sizable, but routine, insider-related sale.

The notice indicates that 62,970 Ionis common shares, valued at about 5,223,748.59, are planned for sale on or around 01/30/2026 via Morgan Stanley Smith Barney. The shares stem from performance stock units granted as compensation under the 2011 Equity Incentive Plan.

The same account sold 44,034 shares over the past three months, generating gross proceeds of 3,294,623.88. Such sales typically reflect diversification or tax planning around equity awards rather than signaling anything about fundamentals, especially as the seller attests to having no undisclosed adverse information.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney 1585 Broadway New York NY 10036	62970	5223748.59	161137930	01/30/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/29/2026	PSUs granted under 2011 Equity Incentive Plan	Ionis Pharmaceuticals			62970	01/29/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Morgan Stanley Smith Barney 1585 Broadway New York NY 10036	Common Stock	01/16/2026	44034	3294623.88

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the latest Form 144 filing reveal about Ionis Pharmaceuticals (IONS)?

The Form 144 shows a planned sale of 62,970 Ionis common shares with an aggregate market value of about 5,223,748.59. The sale will be executed through Morgan Stanley Smith Barney on or around 01/30/2026 on the NASDAQ market.

How many Ionis (IONS) shares has this seller sold recently under Rule 144?

Over the past three months, the same account sold 44,034 Ionis common shares. Those sales generated gross proceeds of 3,294,623.88. The new Form 144 covers an additional 62,970 shares that may be sold following the notice’s effective timing requirements.

Where did the Ionis (IONS) shares in this Form 144 come from?

The 62,970 Ionis common shares come from performance stock units granted under the company’s 2011 Equity Incentive Plan. These PSUs were acquired on 01/29/2026 and delivered as compensation rather than a cash purchase, according to the acquisition information disclosed.

Which broker is handling the planned Ionis (IONS) Rule 144 stock sale?

Morgan Stanley Smith Barney, located at 1585 Broadway, New York, NY 10036, is the broker listed for the planned sale of 62,970 Ionis common shares. The shares are expected to be sold on the NASDAQ exchange as indicated in the notice.

Does the Ionis (IONS) Form 144 mention undisclosed negative information about the company?

The person for whose account the securities are to be sold represents that they do not know any material adverse information about Ionis’s current or prospective operations that has not been publicly disclosed. This representation is part of the standard certification language in the notice.

What class of securities is covered by this Ionis (IONS) Form 144?

The filing covers Ionis common stock. The notice specifies that 62,970 shares of this common equity class may be sold through Morgan Stanley Smith Barney on NASDAQ, following prior sales of 44,034 common shares in the last three months for the same beneficial account.